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Summary
 
Recently, results obtained from mice with targeted inactivations of postreplication DNA mis-
match repair (MMR) genes have been interpreted to demonstrate a direct role for MMR in
antibody variable (V) gene hypermutation. Here we show that mice that do not express the
MMR factor Msh2 have wide-ranging defects in antigen-driven B cell responses. These in-
clude lack of progression of the germinal center (GC) reaction associated with increased intra-
GC apoptosis, severely diminished antigen-specific immunoglobulin G responses, and near
absence of anamnestic responses. Mice heterozygous for the Msh2 deficiency display an “inter-
mediate” phenotype in these regards, suggesting that normal levels of Msh2 expression are crit-
ical for the B cell response. Interpretation of the impact of an MMR deficiency on the
mechanism of V gene somatic hypermutation could be easily confounded by these perturba-
tions.
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P
 
ostreplication mismatch repair (MMR)
 
1
 
 functions to
identify and correct nucleotide misincorporations in
the nascent DNA strand during chromosomal replication in
prokaryotes and eukaryotes (1–3). The genes encoding the
components of this system were initially identified in 
 
Esch-
erichia
 
 
 
coli 
 
as mutations that resulted in increased genome-
wide mutation rates, and were designated Mut genes. A
central component of the postreplication MMR system in
 
E
 
.
 
 coli
 
 is MutS, the protein involved in the recognition of
mispaired nucleotides (1, 4). Homologues of MutS have
been shown to function in a similar manner in 
 
Saccharomy-
ces cerevisiae
 
 and humans (4). Both humans and mice have at
least five homologues of MutS, termed Msh2–6 (4, 5). Re-
cent interest has focused on the human homologues of bac-
terial MMR genes, since mutations in these genes have
been associated with a large fraction of hereditary nonpoly-
posis colorectal cancer kindreds (2, 3). Strains of mice de-
ficient in several of the MSH proteins have now been gen-
erated via gene targeting technology, and most display
expected defects in MMR and a propensity to develop cer-
tain types of cancer. For example, mice deficient in Msh2
are predisposed to the development of a form of pre-T cell
leukemia with onset at 2–3 mo of age, with older mice de-
veloping intestinal and skin neoplasias (6–9). Nevertheless,
Msh2-deficient mice develop normally and are fertile (6, 7, 9).
Recently, several groups have presented evidence ob-
tained from the analysis of antibody V gene somatic hyper-
mutation in mice deficient in MMR proteins. Three of these
groups have concluded that their data support the idea that
MMR proteins are involved in the incorporation or fixation
of mutations in V genes during this process. Cascalho et al.
have proposed that the mammalian MutL homologue Pms2
is directly involved in the introduction of mutations into V
genes (10), whereas Gearhart and colleagues have argued that
both Msh2 (11) and Pms2 (12) alter the spectrum of muta-
tions resulting from the action of the V gene “mutator,” by
preferentially repairing certain types of lesions. Rada et al.
have observed that the V genes in antigen-activated B cells
of Msh2-deficient mice have a reduced V gene hypermuta-
tion frequency, but an increased frequency of mutations at
sites previously identified as “hot spots” in normal mice.
Therefore, they conclude that hypermutation takes place in
sequential Msh2-independent and -dependent phases during
immune responses in normal mice (13).
It is well documented that the somatic hypermutation of
V genes is intimately associated with, and may be a prereq-
uisite for, memory B cell genesis in mice (14–17). In most
of the studies on a possible role of MMR in V gene somatic
hypermutation, the potential for an MMR deficiency re-
sulting in pleiotropic defects in the memory B cell response
 
1
 
Abbreviations used in this paper:
 
 AFC, antibody-forming cell; GC, germi-
nal center; HSA, heat stable antigen; MMR, mismatch repair; NP-CGG,
(4-hydroxy-3-nitrophenyl)acetyl chicken gamma globulin; PALS, periar-
teriolar lymphoid sheath; PI, propidium iodide; TUNEL, terminal deoxy-
nucleotidyl transferase–mediated dUTP nick end labeling. 
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(18, 19) was acknowledged but not directly or extensively
examined. However, preliminary investigation of this issue
has provided support for this idea. Rada et al. observed a
decreased IgG1 response in Msh2 
 
2
 
/
 
2
 
 compared with 
 
1
 
/
 
2
 
mice (13). Moreover, Frey et al. observed that B cells in
the Peyer’s patches of Msh2-deficient mice that are sub-
jected to chronic antigenic stimulation and proliferation
displayed high levels of length variation at the D6Mit59
microsatellite locus (20). Instability at several such micro-
satellite loci is a signature of elevated chromosome-wide
mutation rate (21).
In this report, we present data demonstrating that an
Msh2 deficiency in mice indeed results in wide-ranging de-
fects in the B cell immune response. Among these are an
attenuated progression of the germinal center (GC) reac-
tion, dramatically reduced levels of antigen-induced IgG
isotypes, and a greatly reduced anamnestic response. Signif-
icantly, Msh2 
 
1
 
/
 
2
 
 mice display an “intermediate” pheno-
type in these regards, suggesting that normal levels of ex-
pression of Msh2 are crucial to antigen-driven B cell
proliferation and development. Despite the previously rec-
ognized propensity of Msh2-deficient mice to develop T
cell leukemia (6, 8), T cell numbers and proliferative func-
tion appear essentially normal in young Msh2-deficient
mice. In addition, stimulation of B cells from Msh2-defi-
cient mice in vitro revealed only subtle differences in pro-
liferation, apoptosis, or isotype class switching compared
with wild-type B cells. We discuss how an Msh2 deficiency
might result in these phenotypic outcomes, and how such
pleiotropic effects on the B cell response in vivo could con-
found evaluation of a potential role of the MMR system in
V gene somatic hypermutation.
 
Materials and Methods
 
Msh2-deficient Mice.
 
The line of Msh2-deficient mice used in
this study was created by targeted inactivation of exon 11 of the
 
Msh2
 
 gene, and has been described previously (8). Mice used in
our studies were maintained by brother–sister mating and were of
a mixed C57BL/6 
 
3 
 
129/o/a background. Homozygous knock-
out, heterozygous knockout, and 
 
Msh2
 
 wild-type offspring were
identified using DNA derived from ear-clip tissue, and a previ-
ously described PCR assay (9). Age-matched mice of 7–12 wk of
age were used in all experiments, and littermates were used in in-
dividual experiments when possible.
 
Immunizations and Serology.
 
Preparation of and immunization
with (4-hydroxy-3-nitrophenyl)acetyl chicken gamma globulin
(NP-CGG) were performed as described previously (22–24).
Mice received 100 
 
m
 
g i.p. of antigen in alum for primary immu-
nization, and the same amount of antigen in PBS i.p. for second-
ary immunization. TNP-Ficoll was injected in PBS at a dose of
50 
 
m
 
g i.p. per mouse. Mice were bled via the retroorbital sinus at
various times after immunization, and the levels of anti-NP, anti-
CGG, or anti-TNP antibodies of various isotypes were assayed in
sera obtained from these samples by previously described ELISA
assays (23, 25). These same assays were also used to evaluate anti-
body levels in supernatants obtained from in vitro stimulation of
B cells, with the exception that anti-Ig reagents were used to cap-
ture secreted antibody.
 
Immunohistochemistry and Flow Cytometry Analysis.
 
Spleen isola-
 
tion, flash freezing, sectioning, and immunohistochemistry were
all conducted essentially as described previously (23, 24). The termi-
nal deoxynucleotidyl transferase–mediated dUTP nick end label-
ing (TUNEL) assay was performed on spleen sections to evaluate
numbers of apoptotic nuclei using the ApopTag™ kit obtained
from Oncor, according to the manufacturer’s instructions. Num-
bers of apoptotic nuclei in GCs were counted at 400
 
3
 
 using a
compound microscope. GC sizes were determined by counting
the number of PNA
 
1
 
 cell diameters at 100
 
3
 
 magnification in the
largest GC dimension. Size categories were as follows: small, 10–
29 diameters; medium, 30–39 diameters; and large, 40 or more
diameters. GC microdissection, V
 
l
 
 gene PCR amplification, and
nucleotide sequencing were performed using techniques (26) and
primers (27) described previously.
Flow cytometric analysis of spleen and bone marrow cells
was performed essentially as described previously (28) using
PE-labeled anti-B220 (RA3-6B2; PharMingen), FITC-labeled
anti-IgM (donkey anti–mouse; Jackson ImmunoResearch Labs),
biotin-labeled anti-IgD (SBA-1; Southern Biotechnology Associ-
ates), and FITC-labeled anti-CD24 (heat stable antigen [HSA],
M1/69; PharMingen). Stained cells were analyzed on a Coulter
Epics Profile II or an Epics Elite using the Coulter Elite software.
 
Isolation and In Vitro Stimulation and Analysis of T and B Cells.
 
In some experiments (see legends for details), total lymph node
cells were used as an enriched source of T cells for in vitro analy-
sis. In others, splenic T cells were enriched by treating total
spleen cells with anti–class II (MKD6) and anti-HSA (J11d) mAbs
and guinea pig complement (Rockland), followed by Percoll gra-
dient purification of small dense lymphocytes. The enriched T
cells were incubated with various concentrations of mitogenic re-
agents, antigen, or with 4 
 
3 
 
10
 
5
 
 allogeneic, irradiated (2,000
rads) spleen cells, at 2 
 
3 
 
10
 
5
 
 cells per well in 100 
 
m
 
l RPMI plus
10% FCS. For plate bound anti-CD3 stimulation, 96-well tissue
culture plates were coated with 25 
 
m
 
g/ml 2C11 mAb, followed
by extensive washing with sterile PBS and blocking with media
containing 10% FCS. Proliferation was evaluated 45–50 h after T
cell plating on anti-CD3–coated wells via a pulse of [
 
3
 
H]thymi-
dine for 6–18 h, followed by cell harvesting on glass fiber filters
and scintillation counting.
Small dense splenic B cells were isolated from spleens via T
cell depletion using a cocktail of anti-CD4 (172), anti-CD8
(31M), and anti-Thy1 (polyclonal rabbit anti–mouse; Sigma) an-
tibodies and guinea pig complement, followed by purification of
high-density cells on Percoll gradients. The resulting cells were
incubated in vitro in RPMI plus 10% FCS including various con-
centrations of LPS (Difco), goat anti–mouse IgM F(ab
 
9
 
)
 
2
 
s (Pierce)
or an anti–murine CD40 mAb (FGK45; reference 29). In some
experiments, recombinant murine IL-4 (PeproTech) was in-
cluded in the cultures at 50 ng/ml. To evaluate proliferation,
such cultures were pulsed after 45–50 h with [
 
3
 
H]thymidine, cells
were harvested onto glass fiber filters, and 
 
3
 
H incorporated into
DNA was evaluated by scintillation counting.
To evaluate cell cycle progression and apoptosis, cells were
harvested at various times after initiation of culture, fixed and
permeabilized in 70% EtOH, treated with RNase (Fisher Scien-
tific), and stained with propidium iodide (PI; Sigma) followed by
flow cytometric analysis. Numbers of G1, S, G2, and apoptotic
cells were evaluated using a Coulter Epics Profile II and the Elite
software. Supernatants from such cultures were also harvested at
various times and evaluated for levels of antibodies of various iso-
types, as described above.
 
Analysis of Microsatellite Instability.
 
DNA was isolated as de-
scribed (30) from in vitro cultures of B cells, and instability at the 
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D6Mit59 locus was evaluated using a PCR-based assay essentially
as described previously (9). One of the primers used for this analysis
was end-labeled with 
 
32
 
P using T4 polynucleotide kinase; the PCR
reaction products were then separated on acrylamide/urea DNA
sequencing gels, and the gels were exposed to x-ray film. Microsat-
ellite primer sequences were obtained from the Whitehead Insti-
tute for Genome Research (http://www.genome.wi.mit.edu).
 
Results
 
The GC Reaction Does Not Progress in MSH2-deficient Mice.
 
Our studies were initiated, as were those of others (10–13,
20), to test the idea that a deficiency in MMR might di-
rectly alter the V gene hypermutation process. Since hyper-
mutation takes place predominantly in GCs in normal
mice, we used an immunohistochemical GC microdissec-
tion PCR approach to evaluate levels of V gene mutation
during the immune response to NP-CGG (16, 31). We
observed a relatively normal frequency and chemical spec-
trum of V
 
l
 
 somatic mutation among PCR DNA clones
isolated from 
 
l
 
1
 
 splenic GCs at days 12 and 15 of the pri-
mary NP-CGG response in a pilot study (data not shown).
However, during the course of this study, we found that
the GC reaction in Msh2 
 
2
 
/
 
2
 
 mice was abnormal. The
results of an extensive analysis of this phenomenon are
summarized in Table I. In Msh2 
 
2
 
/
 
2
 
 mice immunized
with 100 
 
m
 
g of NP-CGG in alum, antigen-specific splenic
GCs were present at day 8 after immunization at a normal
 
frequency compared with wild-type mice, but their aver-
age size appeared somewhat smaller, and large GCs (
 
$
 
40
cell diameters) were absent. At 12 d after immunization of
Msh2 
 
2
 
/
 
2
 
 mice, the average size of antigen-specific GCs
had not increased, resulting in continued absence of the large
GCs that make up a sizable percentage of all GCs observed
in 
 
1
 
/
 
1
 
 mice at this time. In addition, at this later time point
the average number of antigen-specific GCs per unit area of
spleen in Msh2 
 
2
 
/
 
2
 
 
 
mice had decreased twofold compared
with day 8, whereas Msh2 
 
1
 
/
 
1
 
 mice showed no significant
difference in this frequency at the two time points. Analysis
of spleens from NP-CGG–immunized Msh2 
 
1
 
/
 
2
 
 mice
revealed an intermediate phenotype with respect to these
alterations, and the intermediate level of total GCs at day
12 in such mice was statistically significant compared with
the values obtained from either 
 
1
 
/
 
1
 
 or 
 
2
 
/
 
2
 
 mice.
Evaluation of levels of apoptosis in the GCs of Msh2 
 
1
 
/
 
1
 
,
 
1
 
/
 
2
 
, and 
 
2
 
/
 
2
 
 mice 8 d after immunization via the
TUNEL assay showed significantly higher levels of apop-
totic nuclei in the small and medium size antigen-specific
GCs of Msh2 
 
2
 
/
 
2
 
 mice compared with 
 
1
 
/
 
1
 
 mice, with
 
1
 
/
 
2
 
 mice displaying intermediate levels of such nuclei
(Fig. 1). Interestingly, the variation in number of apoptotic
nuclei per GC was much larger in Msh2 
 
2
 
/
 
2 
 
compared
with 
 
1
 
/
 
2
 
 and 
 
1
 
/
 
1
 
 mice. The reduced number of anti-
gen-specific GCs at day 12 in Msh2 
 
2
 
/
 
2
 
 mice precluded
obtaining a statistically significant comparison of levels of
apoptotic nuclei at this time point.
Staining of spleen sections from mice immunized 8 and
12 d earlier with NP-CGG with an IgG-specific reagent
showed a reduction in the number of IgG
 
1
 
 B cells in
Figure 1. Levels of apoptotic nuclei in antigen-specific GCs of Msh2-
deficient mice. Mice were immunized with NP-CGG, and spleens were
taken at day 8 after immunization, sectioned, and stained with PNA and
NP, all as described in Materials and Methods. Parallel sections were
stained with PNA, and apoptotic nuclei were elaborated by the TUNEL
assay. Apoptotic nuclei were counted in eight randomly chosen NP1 GCs
of small and medium size (see Table I). Each value obtained is indicated by
a circle in the scatter plots, with values obtained two, three, or fours times
indicated by light gray, dark gray, and black filled circles, respectively.
Filled squares indicate mean value of apoptotic nuclei for each experimen-
tal category. A Student’s t test analysis revealed that the differences in levels
of apoptotic nuclei observed between 1/1 and 2/2 mice in both GC
size categories were statistically significant at the 90% confidence level.
 
Table I.
 
Antigen-specific GC Numbers and Sizes in
Msh2-deficient Mice
 
Total NP
 
1
 
 GCs per 10
 
3
 
 field
 
*
 
Small Medium Large
Day 8
 
1
 
/
 
1
 
2.2
 
 6
 
 1.6 3.5 
 
6
 
 2.17 1.2 
 
6
 
 0.98
 
‡
 
Total 6.83 
 
6
 
 2.56
 
1
 
/
 
2
 
3.83 
 
6
 
 1.17 2.33 
 
6
 
 1.03 0.5 
 
6
 
 0.84
 
Total 6.67 
 
6
 
 2.25
 
2
 
/2 3.33 6 2.07 3.33 6 2.58 0‡
Total 6.67 6 1.37
Day 12
1/1 2.17 6 1.17 1.83 6 0.75 1.67 6 1.33¶1
Total 5.67 6 1.5§**
1/2 3.25 6 1.89 1.25 6 1.26 0.25 6 0.5¶
Total 4.75 6 1.70i**
2/2 1.67 6 1.5 2.0 6 1.41 01
Total 3.67 6 1.37§i
*Values were obtained from three mice of each genotype. Two ran-
dom fields per section and two sections per mouse from different areas
of the single spleen were analyzed.
‡, §, i, ¶, **, 1Value pairs that pass the Student’s t test at the 90% confi-
dence level.474 B Cell Responses in Msh2-deficient Mice
the GCs of Msh2 2/2 mice relative to 1/1 mice (data
not shown). Moreover, the periarteriolar lymphoid sheath
(PALS)-associated antibody-forming cell (AFC) focus reac-
tion, a predominant component of the early primary anti–
NP-CGG response (22, 32), was also substantially reduced
in Msh2 2/2 spleens (Fig. 2). This was observed using
both antigen- and IgG-specific staining. Again, Msh2 1/2
mice displayed an intermediate phenotype with respect to
these alterations (Fig. 2). Despite these differences, no ob-
vious abnormalities in splenic architecture, the size of other
splenic B and T cell microenvironments, size and location
of follicular dendritic cell networks, or locales of antigen-
specific B cell proliferation and differentiation were ob-
served among Msh2 1/1, 1/2, and 2/2 mice during
these studies.
Severely Reduced Mature Serum Antibody Responses in Msh2-
deficient Mice. These observations led us to conduct detailed
analysis of the anti–NP-CGG serum antibody responses of
Msh2-deficient mice. As shown in Fig. 3 A, at early stages of
this response, antigen-specific IgM levels were only slightly
lower in Msh2 1/2 and 2/2 mice compared with 1/1
mice. However, dramatic differences in the levels of NP-
specific k, l, and IgG isotypes were apparent between Msh2
1/1 and 2/2 mice at all times in the primary response,
with Msh2 1/2 mice displaying an intermediate phenotype
in most cases (Fig. 3, A and B). Msh2 1/2 mice also
showed a delayed serum IgG1 response (peaking at day 21
instead of 14), and expressed increased levels of IgG2a,
although this isotype was a minor component of the total
response in all mice. Also readily apparent was the severely
diminished or reduced secondary serum antibody response in
Msh2 2/2 and 1/2 mice, respectively. In 2/2 mice, this
secondary response was of a magnitude not noticeably differ-
ent from peak levels in the primary response in most assays.
This result was not idiosyncratic to the anti-NP response, as
the secondary response to the carrier, CGG, was also severely
blunted in 2/2 mice and reduced in 1/2 mice (Fig. 3 C).
Analysis of the serum antibody response to TNP-Ficoll, a T
cell–independent antigen, revealed analogous IgM responses
in 1/1 and 2/2 mice, but the total (kappa) anti-TNP re-
Figure 2. GC and PALS focus responses in the
spleens of Msh2-deficient mice at day 8 after immu-
nization. Mice were immunized with NP-CGG, and
spleens were taken at 8 d after immunization and sec-
tioned for immunohistochemistry, all as described in
Materials and Methods. Parallel sections were stained
either with (A) PNA (red) and NP (blue), or with (B)
PNA (blue) and a polyclonal anti-IgG reagent (red).
Notice the intense antigen- and IgG-specific staining
at the edges of the white pulp in the 1/1 spleen sec-
tions, characteristic of the PALS AFC focus response.
This reaction is obviously reduced in 1/2 spleens
and nearly absent in 2/2 spleens. At day 8 of the
response, reduction in the number of GCs in Msh2
2/2 mice has not occurred, but at day 12, when the
PALS focus response has waned, there are twofold
fewer GCs in 2/2 compared with 1/1 spleens,
and the average size of these GCs is much smaller
(see Table I).475 Vora et al.
sponse decayed more rapidly in Msh2 2/2 mice. This more
rapid decay appeared to be accounted for by a severe defi-
ciency in the IgG3 response, particularly at late times after
immunization (Fig. 3 D). Interestingly, total serum IgG lev-
els were found not to differ significantly in Msh2 1/1, 1/2,
and 2/2 mice (data not shown), suggesting that long-term
homeostatic regulation of these levels is not perturbed by an
Msh2 deficiency.
Peripheral B Cell, T Cell, and Bone Marrow B Cell Com-
partments in Msh2-deficient Mice. Alteration of the T cell–
dependent B cell response in Msh2-deficient mice could
result from preexisting abnormalities in the T cell com-
partment, the B cell compartment, or both. Flow cyto-
metric analysis of splenic B lymphocytes revealed no ap-
parent abnormalities in numbers of mature and immature
subsets in Msh2-deficient mice (Fig. 4). Similar analyses of
the T cell compartment revealed no obvious differences
between Msh2 1/1 and 2/2 mice (data not shown).
These observations are consistent with previous publica-
tions indicating that the splenic lymphoid compartment of
Figure 3. Serum antibody responses of Msh2-deficient mice. Immunization was performed with either NP-CGG (A, B, and C) or TNP-Ficoll (D), as de-
scribed in Materials and Methods, and mice were bled at various times thereafter. Levels of antigen-specific antibody of a particular isotype were determined by
ELISA. In many of these assays, anti-NP mAbs with similar affinities for NP were used as standards, allowing the results to be presented as micrograms per milli-
liter of these standards. In other assays, relative levels of antigen-binding antibodies in different sera were determined using serial dilutions. The points at which
the resulting OD curves were 50% maximal were then used to calculate the relative dilution factor giving an equivalent OD for each serum sample. The data
illustrated in A and C were obtaining using sera pooled from at least three different animals of the each genotype. The data illustrated in B and D were obtained
from at least three individual sera per time point, and error bars are shown (except for the 1/1 anti–TNP-Ficoll data, which were obtained from one animal).476 B Cell Responses in Msh2-deficient Mice
Msh2-deficient mice is overtly normal (6–8). Analysis of
B lineage cells in the bone marrow of such mice revealed
a slight decrease in the proportion of B2201 immature
IgM1, IgD2 B cells in Msh2 2/2 compared with 1/1
mice, but a more dramatic four- to fivefold reduction in
mature “recirculating” B2201, IgM1, IgD1 B cells in 2/2
mice. The latter result is consistent with the previous re-
sults of Rada et al. (13).
In Vitro Proliferative Responses of Msh2-deficient T Cells.
To assess generic T cell activation and proliferation func-
tion, in vitro stimulations of lymph node and splenic T cells
were performed. No significant differences in anti-CD3–,
Con A–, or alloantigen-induced proliferative responses were
observed among Msh2 1/1, 1/2, or 2/2 T cells (Fig.
5). In addition, KLH-primed lymph node T cells obtained
from Msh2-deficient mice proliferated in response to re-
stimulation with KLH in vitro to an extent that did not dif-
fer reproducibly from wild-type cells (data not shown).
Proliferative and Apoptotic Responses of Msh2-deficient B
Cells In Vitro. The lack of evidence for defects in T cell
function and mature peripheral B cell numbers and matu-
rity in Msh2 mice prompted a detailed analysis of B cell re-
sponses in vitro. Small dense B cells were purified from
Msh2 1/1, 1/2, and 2/2 mice and stimulated with
anti-IgM F(ab9)2 fragments, LPS, or a mitogenic anti-
CD40 mAb in vitro. The cultures were then evaluated for
cell cycle progression via [3H]thymidine incorporation.
Cell cycle progression and apoptosis were also evaluated us-
ing PI–flow cytometric DNA content analysis. Msh2 2/2 B
cells displayed only slightly reduced proliferation that was
not statistically significant compared with 1/1 B cells, ex-
cept at the highest concentrations of stimulant (Fig. 6). PI
cell cycle analysis revealed only minor differences in cell
cycle progression and apoptosis induced by these same
stimuli among the various types of B cells during a 4-d cul-
ture period. Msh2 2/2 cultures contained only slightly
elevated levels of apoptotic cells at early time points in a
few experiments (data not shown).
In Vitro Isotype Class Switching by Msh2-deficient B Cells.
Since our serological and immunohistochemical analysis of
the B cell response of Msh2-deficient mice revealed a se-
vere attenuation of the IgG response, induction of isotype
class switching in vitro was examined using small dense
Figure 4. Levels of B cells in bone marrow and spleens of Msh2-defi-
cient mice. Numbers and proportions of B2201 cells expressing cell sur-
face antigens diagnostic of mature B cells were measured in spleen and
bone marrow cells from at least three animals per genotype via flow cy-
tometry, as described in Materials and Methods. In bone marrow, the
proportion of B2201 cells that expressed surface IgM but not IgD was
measured to evaluate immature B cell levels, and the proportion of B2201
cells that expressed both isotypes was used to evaluate levels of mature,
recirculating cells. B cell numbers and maturity in the spleen were evalu-
ated using B220 and levels of expression of HSA.
Figure 5. In vitro proliferative responses of Msh2-deficient T cells. Total lymph node cells were stimulated with either 4 mg/ml Con A or irradiated
spleen cells from BALB.K mice (allo-MHC) for 48 h, as described in Materials and Methods, and pulsed with [3H]thymidine to measure proliferation.
Plate-bound anti-CD3 stimulation was also performed in this fashion (see Materials and Methods), but using splenic T cells enriched as described. The
cells used for each experiment were derived from at least two mice of each genotype.477 Vora et al.
splenic B cells. B cells were cultured with LPS, which re-
sults in low levels of switching to IgG3 and IgG2b in nor-
mal B cells, or with LPS plus IL-4, which suppresses switch-
ing to IgG3 and drives efficient switching to IgG1 and IgE
isotypes in normal B cells (33). Levels of class-switched
IgG1 and IgG3–secreted antibody were then determined by
ELISA. Msh2 1/1,  1/2, and 2/2 B cells stimulated
with LPS gave rise to levels of IgG3 that did not differ
greatly, and Msh2 2/2 B cells produced only slightly re-
duced amounts of this isotype (Fig. 7). Little or no IgG1 was
produced by any of these cell types in response to LPS. In
response to stimulation with LPS plus IL-4, Msh2 1/1,
1/2, and 2/2 B cells gave rise to similar levels of IgG1,
and little IgG3. These data argue that the regulation and ef-
ficiency of isotype class switching in vitro are not greatly
perturbed by an Msh2 deficiency in B cells.
Discussion
Mice lacking Msh2 display a striking defect in their abil-
ity to sustain a B cell response. Moreover, mice containing
only one copy of the functional Msh2 gene (resulting in
50% of the wild-type level of Msh2 protein expression [7])
display an “intermediate” phenotype in this regard, indicating
that even a slight reduction in Msh2 activity can perturb
this response. It should be noted that the intermediate B
cell response defect displayed by Msh2 1/2 mice makes
them inappropriate controls for studies on the effects of an
Msh2 deficiency in vivo. Msh2 deficiency results in an in-
hibition of the progression of the GC reaction, dramati-
cally reduced levels of IgG-producing AFCs and antigen-
induced IgG serum antibody, and a blunted anamnestic
response. We have also observed that Msh2 expression is
elevated in GCs (Vora, K.A., R. Fishel, and T. Manser,
unpublished observations), consistent with the idea that this
protein plays a critical role in B cell development in this
microenvironment.
Nonetheless, why an Msh2 deficiency leads to such a se-
vere attenuation of mature B cell responses in vivo remains
a subject of speculation. Although we found that T cell
numbers and proliferative function in vitro were normal in
Msh2 2/2 mice, a more detailed analysis of Th function
might have exposed differences between antigen-primed
wild-type and Msh2-deficient T cells. A complicating fac-
tor in this regard is that in an environment where B cell
function is deficient, defects in levels of T cell activation or
differentiation may arise secondarily (34). Since Msh2 2/2
mice are predisposed to the development of pre-T cell leu-
kemia, it is tempting to speculate that general T cell physi-
ology may be perturbed in these mice. Our experiments
were performed in young mice with no evidence of T cell
abnormalities. In addition, Msh2 1/2 mice, which do not
frequently develop T cell leukemia (8; Cranston, A., and
R. Fishel, unpublished observations), displayed obviously
altered B cell responses, and the immune response to the T
cell–independent antigen TNP-Ficoll was reduced in Msh2
2/2 mice. Finally, initiation of the GC reaction, a T cell–
dependent process, appeared normal in Msh2-deficient
mice. Nevertheless, given the previous conclusions of oth-
ers that the GC reaction appears to require lower levels of
T cell help than does the AFC response (35, 36), and that
class switching to many IgG isotypes is driven by Th cells
(33), a primary or secondary defect in the development of
an efficient Th response in Msh2-deficient mice must still
Figure 6. In vitro proliferative responses
of Msh2-deficient B cells. Small dense
splenic B cells were purified from pools of
cells derived from three mice of each geno-
type, as described in Materials and Methods,
and cultured for 45–50 h with the indicated
concentrations of LPS, a polyclonal goat
anti–mouse IgM F(ab9)2 preparation, or the
mitogenic anti–mouse CD40 mAb FGK45.
Cell proliferation was then evaluated via a
12–16-h pulse of [3H]thymidine, also as de-
scribed in Materials and Methods. All cul-
ture conditions were performed in tripli-
cate, and error bars are shown. The data
shown are representative of the results of
three independent experiments.
Figure 7. IgG expression by Msh2-deficient B cells in vitro. Small
dense splenic B cells derived from pools of cells obtained from three mice
of each genotype were cultured for 4.5 d with either LPS (25 mg/ml) or
LPS (25 mg/ml) and recombinant murine IL-4 (50 ng/ml), and superna-
tants were harvested. Levels of total IgG3 and IgG1 in these supernatants
were then determined by ELISA, as described in Materials and Methods.
All assays were performed in triplicate, and error bars are shown.478 B Cell Responses in Msh2-deficient Mice
be considered. Resolution of this issue will require the
construction of mice with selective Msh2 deficiencies in
the B and T cell compartments.
In principle, an intrinsic B cell defect due to Msh2 defi-
ciency might result from perturbations in any of the so-
matic DNA alteration pathways essential to normal B cell
development. Taken together, however, our data argue
against this possibility. Analysis of B lineage cells in the
bone marrow of Msh2 2/2 mice revealed a major defi-
ciency in the size of the mature, IgM1, IgD1 “recirculating”
subpopulation, but immature IgM1, IgD2 B cell numbers
were only slightly reduced and peripheral B cell numbers
and maturity levels appeared normal, consistent with the
idea that primary B cell development is not greatly altered
due to an Msh2 deficiency. As suggested previously (18),
an increased rate of V gene hypermutation due to the ab-
sence of a “counteracting” MMR system might dramati-
cally increase the frequency of generation of nonfunctional
antigen receptors on GC B cells, resulting in substantial in-
creases in GC cell death rate. However, this would not eas-
ily explain the severely attenuated PALS AFC focus and T
cell–independent B cell responses we observed, since V
gene mutation does not take place at a high rate during
these responses (26, 37). Finally, the possibility that Msh2
might be involved in class switch recombination, while in-
triguing due to its documented role in suppression of ho-
meologous recombination (38), is not supported by our
finding that Msh2-deficient B cells can efficiently and accu-
rately class switch in vitro.
On the other hand, our data strongly suggest that the ef-
fects of an Msh2 deficiency on B cell function do not be-
come manifest until the stages of antigen-driven responses
characterized by high rates of proliferation. The early stages
of the primary T cell–dependent antigen-driven response,
including IgM production and initiation of the GC reac-
tion, were not greatly affected by an Msh2 deficiency. We
also observed a normal early IgM response to TNP-Ficoll.
In contrast, GC expansion in Msh2 2/2 mice appears
blocked, and this alteration is associated with a substantially
higher frequency of apoptotic cells in GCs. The observa-
tion that the PALS AFC focus response is severely attenu-
ated in Msh2-deficient mice could also be explained by the
rapid clonal expansion necessary for this response (22, 32),
or by the derivation of precursors of this response from the
GC reaction (39). The reason for the deficiency in the ma-
ture IgM1, IgD1 recirculating bone marrow B cell popula-
tion in Msh2 2/2 mice is more difficult to explain, but
might indicate a reduced peripheral B cell life span, or der-
ivation of a subset of this population from the memory B
cell pathway.
Interestingly, we observed more variability in the num-
ber of apoptotic nuclei per GC in Msh2 2/2 mice com-
pared with controls (Fig. 1). In normal mice, intra-GC B
cell apoptosis is thought to result from negative selection of
autoreactive B cells and a lack of positive selection of B
cells with low affinities for antigen (40–44). The increased
and greater variability in numbers of GC apoptotic nuclei
characteristic of Msh2-deficient mice is consistent with the
superimposition of another, highly stochastic process lead-
ing to intra-GC apoptosis. A generic defect in high rate B
cell proliferation due to increased genome-wide mutation
rate (the “mutator” phenotype) is a reasonable candidate for
this process. The perturbations we observed in IgG expres-
sion in Msh2-deficient B cell responses could well result
secondarily from such a proliferative defect, as class switch-
ing requires cell division and usually takes place after a pe-
riod of clonal expansion (22, 33).
These considerations raise the question of why we ob-
served only subtle changes in Msh2 2/2 B cell prolifera-
tion, apoptosis, and class switching during our in vitro
studies. The answer may simply relate to the fact that rates
and extents of B cell proliferation approaching those char-
acteristic of certain stages of antigen-driven B cell develop-
ment are not attained by most B cells subjected to in vitro
stimulation (45). Moreover, B cells undergoing the initial
stages of apoptotic death are probably rapidly engulfed by
phagocytic cells in vivo, but may remain intact for ex-
tended periods in vitro. Under conditions of low to mod-
erate rates of clonal expansion of Msh2-deficient B cells,
DNA lesions normally recognized by Msh2-containing
complexes may be recognized and repaired, albeit less effi-
ciently, by other factions of the DNA repair system. How-
ever, as cell cycle time decreases, a less efficient MMR sys-
tem might well become limiting for clonal expansion.
Accumulation of point mutations in genes pivotal in regu-
lating cell viability, or a sudden block to cell cycle progres-
sion due to more severe lesions whose repair, suppression,
or detection is normally in part mediated by Msh2 (such as
double strand breaks [46] or homeologous recombination
products [38]) would likely culminate in induction of apop-
totic pathways and cell death. Indeed, analysis of MSH2-defi-
cient Peyer’s patch GC B cells, a population undergoing
chronic, high rate proliferation, revealed high levels of insta-
bility at the D6Mit59 microsatellite locus (20). In contrast,
when we performed a similar analysis of this locus in Msh2
1/1, 1/2, and 2/2 B cells stimulated for 5 d in vitro with
anti-IgM, LPS, or anti-CD40, no instability at this locus
could be detected (data not shown). Clearly, these observa-
tions warrant a more detailed analysis of Msh2-deficient B
cell cycle progression, life span, and genome stability in vivo.
Previous conclusions regarding the effect of MMR defi-
ciencies on V gene hypermutation have been garnered
largely from the analysis of the V gene products of antigen-
driven B cell responses taking place in vivo (11–13, 20). As
our data show that the T cell–dependent B cell response,
during which the hypermutation process takes place, is
grossly perturbed by such a deficiency, these data mandate
a reevaluation of these conclusions. Memory B cell devel-
opment takes place simultaneously in a single animal in
many distinct lymphoid microenvironments, the most im-
portant of which are probably the GCs (40, 47, 48). Be-
cause the B cell clonal composition of a given GC is lim-
ited (31, 49), the nature of antigen selection forces and
clonal proliferation will vary in different GCs. Such differ-
ences are amplified by the rather random nature of hyper-
mutation, resulting in very different V region mutant rep-479 Vora et al.
ertoires in different GCs. In addition, levels of V gene
hypermutation have been observed to vary in GCs at the
same time during an immune response (50). Thus, since
GCs are “independent islands of antibody V region somatic
evolution” (22, 51), the impact of an MMR deficiency on
the progression of the GC reaction may vary dramatically
from GC to GC, depending on the variables discussed
above.
These observations make it clear that sampling biases are
likely to be problematic in the analysis of the effects of
MMR deficiencies on V gene somatic hypermutation.
Such sampling biases could result from substantial GC to
GC, and even mouse to mouse, variation in the effects of
an MMR deficiency on memory B cell genesis. For exam-
ple, in our analysis of Vl mutation in Msh2 2/2 mice, we
chose to microdissect only the GCs that stained strongly
with NP for PCR recovery of Vl genes. This limited anal-
ysis revealed approximately normal frequencies of GC V
gene mutation, supporting the idea that Msh2 is not in-
volved in the hypermutation process (20, 27). However,
such NP11 GCs become progressively rare in Msh2 2/2
compared with 1/1 mice, and those we picked might
only have been representative of a small clonal subpopula-
tion that had not succumbed to the stochastic effects of ab-
sence of Msh2, perhaps due to a lower rate of proliferation.
Indeed, if high proliferation rate predisposes a B cell
clone to death in an Msh2-deficient situation, the outcome
of antigen-driven clonal selection during B cell responses
may often be reversed in Msh2-deficient mice compared
with normal mice, to favor those antigen-stimulated clones
that exit the cell cycle earliest during the response. Some-
what analogous arguments have been presented by Frey et al.
(20). Such biases might be further exacerbated when the
memory B cell compartment is sampled, as even in normal
mice this population is derived from a minor fraction of all
clones that participate in the primary GC reaction (15, 31,
52, 53). Overall, an Msh2 deficiency may result in majority
representation of responding B cells that have failed to
complete or activate normal steps in memory B cell gene-
sis, including steps in clonal expansion, selection, and V
gene hypermutation. For example, Kuo and Sklar (54)
have observed that the mammalian homologue of the
MutM gene (8-oxyguanine DNA glycosylase) is highly in-
duced in the rapidly proliferating B cells of GCs. This en-
zyme is involved in the pathway leading to repair of oxida-
tively damaged G nucleotides in DNA (55). Since an Msh2
deficiency attenuates progression of the GC reaction, per-
haps via promoting the death of cells undergoing rapid pro-
liferation, such a deficiency could result, secondarily, in
overrepresentation of GC B cells that have not induced
MutM. This could lead to a preferential sampling of muta-
tions at germline G residues, if oxidative damage to these
residues was elevated during the GC reaction. Such a sce-
nario could explain the observations of Jacobs et al. (27),
Phung et al. (11), and Rada et al. (13) that V gene muta-
tions sampled on one strand in Msh2-deficient mice are
observed predominantly at positions in which a germline G
or C nucleotide was present.
Following from these arguments, the differences in hy-
permutation frequency and pattern observed in previous
studies of MMR-deficient mice (10–13, 20) could well
have resulted from biases in sampling of the V gene prod-
ucts of memory B cell responses (18, 19). Thus, while these
differences are intriguing, whether MMR proteins play any
direct role in the generation, fixation, or repair of DNA le-
sions during the hypermutation process remains an unre-
solved question. Clearly, if such a role is to be accurately
evaluated in the future, experiments will need to be con-
ducted under conditions where the effects of MMR defi-
ciencies or defects on other aspects of B cell differentiation
are minimized.
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